Sponsor content
181 result(s) found, displaying 11 to 20
-
Jul-2025Prescription medicine evaluationActive ingredient: deucravacitinib.
-
Prescription medicine registrationActive ingredients: nivolumab.
-
Prescription medicine registrationActive ingredients: Ipilimumab.
-
Cancellation by sponsorRequested by Bristol-Myers Squibb Australia Pty Ltd
-
Prescription medicine registrationActive ingredients: nivolumab.
-
Prescription medicine registrationActive ingredients: Ipilimumab.
-
Prescription medicine registrationActive ingredients: fedratinib hydrochloride.
-
Prescription medicine registrationActive ingredients: nivolumab.
-
Prescription medicine registrationActive ingredients: nivolumab.
-
Australian public assessment report (AusPar)Opdivo (nivolumab), in combination with platinum-doublet chemotherapy, was approved for the neoadjuvant treatment of patients with resectable non-small cell lung cancer.